Prolonged in-vivo half-life of factor VIIa by fusion to albumin.


For the treatment of haemophilia patients with inhibitors, recombinant factor VIIa (rFVIIa) is available as a therapeutic option to control bleeding episodes with a good balance of safety and efficacy. However, the short in-vivo half-life of approximately 2.5 hours makes multiple injections necessary, which is inconvenient for both physicians and patients… (More)
DOI: 10.1160/TH07-08-0525


Figures and Tables

Sorry, we couldn't extract any figures or tables for this paper.

Slides referencing similar topics